Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 64 of 157 for:    Idiopathic Dilated Cardiomyopathy

Exome Sequencing Study in Cardiomyopathy to Identify New Risk Variants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03754101
Recruitment Status : Recruiting
First Posted : November 27, 2018
Last Update Posted : November 27, 2018
Sponsor:
Information provided by (Responsible Party):
Dao Wen Wang, Tongji Hospital

Brief Summary:
Genetic mutations has been proved to be associated wth the onset of cardiomyopathy. In the present study, we intend to identify new related variants or genes. From March, 2003 to November, 2017, patients diagnosed as cardiomyopathy were consecutively recruited, and their sampled were drawn from peripheral blood. Paired control group were also enrolled. The whole exome sequencing was used to find out the variants associated with the onset of cardiomyopathy and its prognosis.

Condition or disease
Dilated Cardiomyopathy

Layout table for study information
Study Type : Observational
Estimated Enrollment : 4000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Exome Sequencing Study in Cardiomyopathy to Identify New Risk Variants
Actual Study Start Date : March 3, 2003
Estimated Primary Completion Date : October 31, 2019
Estimated Study Completion Date : October 31, 2019





Primary Outcome Measures :
  1. Cardiovascular death confirmed by death comfirmation or interview with the relatives [ Time Frame: up to 24 months ]
    Death from cardiovascular causes and any unknown death unless there was another certain cause

  2. Heart transplantation confirmed by medical record [ Time Frame: up to 24 months ]
    Heart transplantation within 24 months


Secondary Outcome Measures :
  1. All cause death confirmed by death comfirmation or interview with the relatives [ Time Frame: up to 24 months ]
    Any death at hospital or after discharge

  2. Heart failure recurring confirmed by medical record [ Time Frame: up to 24 months ]
    Recurrence of heart failure at hospital or after discharge


Other Outcome Measures:
  1. Readmission because of cardiovascular diseases confirmed by medical record [ Time Frame: up to 24 months ]
    Readmission because of cardiovascular diseases within 24 months



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
hospitalized patients with cardiomyopathy will be enrolled in this study
Criteria

Inclusion Criteria:

· Patients diagnosed as cardiomyopathy according to the definition of American Heart Association

Exclusion Criteria:

  • Uncontrolled hypertension significant valvular disease
  • Mild ischemic heart disease
  • Significant systemic infection
  • Thyroid-induced cardiomyopathy
  • Excessive alcohol consumption
  • Precious cancer treatment including irradiation
  • Refusal to participate in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03754101


Contacts
Layout table for location contacts
Contact: Chenze Li, MD candidate 86-27-83663280 lichenze@126.com

Locations
Layout table for location information
China, Hubei
Tongji Hospital Recruiting
Wuhan, Hubei, China, 430030
Contact: Chenze Li, MD candidate    86-27-83663280    lichenze@126.com   
Sponsors and Collaborators
Tongji Hospital
Investigators
Layout table for investigator information
Study Chair: Dao Wen Wang, Doctor Tongji Hospital,Wuhan, Hubei, China, 430030

Layout table for additonal information
Responsible Party: Dao Wen Wang, Professor, Tongji Hospital
ClinicalTrials.gov Identifier: NCT03754101     History of Changes
Other Study ID Numbers: TJ-DM-GENE
First Posted: November 27, 2018    Key Record Dates
Last Update Posted: November 27, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiomyopathies
Cardiomyopathy, Dilated
Heart Diseases
Cardiovascular Diseases
Cardiomegaly